University of Utah’s and University of Wisconsin’s COVID-19 experience

Emerging strategies from the University of Utah and University of Wisconsin to combat COVID-19

 

On this episode of Modern Practice, we’ll hear from experts at two leading medical centers who discuss the use of investigational medications to treat patients infected with COVID-19, including the drugs chloroquine, hydroxychloroquine, remdesivir and others.

 

Guest speakers:

Emily Spivak, MD, MHS

Associate Professor of Medicine

Medical Director

Antimicrobial Stewardship Program

University of Utah Health

 

Lucas Schulz, PharmD, BCIDP

Clinical Coordinator

Infectious Diseases

UW Health

 

Moderators:

Tomas Villanueva, DO, MBA, FACPE, SFHM

Associate Vice President

Clinical Resources

Vizient

 

Lindsay Mayer, MSN
Senior Director

Programs, PI Collaboratives

Vizient

 

Show Notes:

[01:10] Overview of investigational agents

[01:50] Chloroquine/hydroxychloroquine

[05:10] Adding azithromycin to the treatment

[06:43] Pros and cons for chloroquine/hydroxychloroquine

[09:22] Lopinavir/ritonavir

[10:25] Remdesivir

[14:00] COVID-19 treatment guideline

[15:40] Further comments on azithromycin

[17:54] Supportive care is the only recommended care

 

For additional information on COVID-19 and how Vizient is supporting our members, visit vizientinc.com